PuSH - Publikationsserver des Helmholtz Zentrums München

Nagarajan, D.* ; Parracho, R.T.* ; Corujo, D.* ; Xie, M.* ; Kutkaite, G. ; Olsen, T.K.* ; Rúbies Bedós, M.* ; Salehi, M.* ; Baryawno, N.* ; Menden, M.P. ; Chen, X.* ; Buschbeck, M.* ; Mao, Y.*

Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma.

J. Clin. Invest.:e175310 (2024)
Postprint DOI PMC
Open Access Gold
Childhood neuroblastoma with MYCN-amplification is classified as high-risk and often relapses after intensive treatments. Immune checkpoint blockade therapy against the PD-1/L1 axis shows limited efficacy in neuroblastoma patients and the cancer intrinsic immune regulatory network is poorly understood. Here, we leverage genome-wide CRISPR/Cas9 screens and identify H2AFY as a resistance gene to the clinically approved PD-1 blocking antibody, nivolumab. Analysis of single-cell RNA sequencing datasets reveals that H2AFY mRNA is enriched in adrenergic cancer cells and is associated with worse patient survival. Genetic deletion of H2afy in MYCN-driven neuroblastoma cells reverts in vivo resistance to PD-1 blockade by eliciting activation of the adaptive and innate immunity. Mapping of the epigenetic and translational landscape demonstrates that H2afy deletion promotes cell transition to a mesenchymal-like state. With a multi-omics approach, we uncover H2AFY-associated genes that are functionally relevant and prognostic in patients. Altogether, our study elucidates the role of H2AFY as an epigenetic gatekeeper for cell states and immunogenicity in high-risk neuroblastoma.
Impact Factor
Scopus SNIP
Altmetric
13.300
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Cancer ; Cancer Immunotherapy ; Immunology ; Oncology
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 0021-9738
e-ISSN 1558-8238
Quellenangaben Band: , Heft: , Seiten: , Artikelnummer: e175310 Supplement: ,
Verlag American Society of Clinical Investigation
Begutachtungsstatus Peer reviewed
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-554700-001
PubMed ID 39255035
Erfassungsdatum 2024-10-15